Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...

Truist lowered the firm’s price target on Regeneron (REGN) to $975 from $1,004 and keeps a Buy rating on the shares. The firm notes Regeneron has pulled back over the last few quarters on Eylea ...

“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative ...

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs ...

This edition of Org Chart has news on a number of centers around campus, as well as a new endowed chair, a key financial position and more. Geophysicist Amanda Thomas has been named the inaugural ...

April 22 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially ...